(Q40270415)

19 September 2017

title

Malignant pheochromocytoma: state of the field with future projections (English)

1 reference

malignant pheochromocytoma

19 September 2017

1 reference

1 reference

Håkan Ahlman

1

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Annals of the New York Academy of Sciences

19 September 2017

published in

1 reference

19 September 2017

volume

1073

1 reference

19 September 2017

page(s)

449-464

1 reference

Molecular dissection of the secretory pathway

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Expression cloning of a reserpine-sensitive vesicular monoamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Increased expression of cyclooxygenase-2 in malignant pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Biochemical diagnosis of pheochromocytoma: which test is best?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Long-term outcome of a large series of patients surgically treated for pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Clinical spectrum and outcome of functional extraadrenal paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Clinical experience over 48 years with pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

The value of plasma markers for the clinical behaviour of phaeochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Pheochromocytomas: can malignant potential be predicted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

The management of benign and malignant pheochromocytoma and abdominal paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Germ-line mutations in nonsyndromic pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Malignant pheochromocytoma: current status and initiatives for future progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

High-level expression of receptor tyrosine kinase Ret and responsiveness to Ret-activating ligands in pheochromocytoma cell lines from neurofibromatosis knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Indications and results of liver transplantation in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Interventional treatment of the carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Perioperative management of pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

The IKK NF-kappa B system: a treasure trove for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

Liver transplantation for neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.049

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1353.049

1 reference

19 September 2017

1 reference